ACE2 and pulmonary arterial hypertension: The innovative clinical study by Hemnes et al. used a recombinant form of human ACE2 (GSK2586881) and showed that infusion of a single dose is well-tolerated and effective in PAH patients as it improves cardiac output and pulmonary vascular resistance [48].